News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,409 Results
Type
Article (41814)
Company Profile (473)
Press Release (663122)
Section
Business (208496)
Career Advice (2013)
Deals (35970)
Drug Delivery (97)
Drug Development (83405)
Employer Resources (169)
FDA (16357)
Job Trends (15055)
News (352303)
Policy (32999)
Tag
Academia (2619)
Alliances (50780)
Alzheimer's disease (1333)
Approvals (16310)
Artificial intelligence (172)
Bankruptcy (363)
Best Places to Work (11804)
Biotechnology (355)
Breast cancer (209)
Cancer (1561)
Cardiovascular disease (130)
Career advice (1678)
CAR-T (111)
Cell therapy (330)
Clinical research (66687)
Collaboration (593)
Compensation (311)
COVID-19 (2609)
C-suite (138)
Data (1490)
Diabetes (190)
Diagnostics (6253)
Earnings (86248)
Employer resources (147)
Events (113839)
Executive appointments (483)
FDA (17140)
Funding (533)
Gene therapy (234)
GLP-1 (654)
Government (4423)
Healthcare (19067)
Infectious disease (2706)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16667)
Job creations (3696)
Job search strategy (1430)
Layoffs (451)
Legal (7945)
Lung cancer (228)
Manufacturing (222)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19550)
Metabolic disorders (518)
Neuroscience (1718)
NextGen: Class of 2025 (6747)
Non-profit (4541)
Northern California (1883)
Obesity (296)
Opinion (205)
Patents (134)
People (57992)
Phase I (20936)
Phase II (29431)
Phase III (21758)
Pipeline (623)
Postmarket research (2599)
Preclinical (8946)
Radiopharmaceuticals (255)
Rare diseases (302)
Real estate (6001)
Regulatory (22230)
Research institute (2407)
Resumes & cover letters (351)
Southern California (1638)
Startups (3751)
United States (17021)
Vaccines (595)
Weight loss (211)
Date
Today (26)
Last 7 days (442)
Last 30 days (1899)
Last 365 days (35908)
2025 (1646)
2024 (36337)
2023 (41017)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (211)
Asia (38792)
Australia (6448)
California (4329)
Canada (1558)
China (369)
Colorado (193)
Connecticut (214)
Europe (84565)
Florida (600)
Georgia (146)
Illinois (428)
Indiana (242)
Maryland (698)
Massachusetts (3406)
Michigan (184)
Minnesota (320)
New Jersey (1203)
New York (1215)
North Carolina (840)
Northern California (1883)
Ohio (154)
Pennsylvania (1006)
South America (1107)
Southern California (1638)
Texas (626)
Utah (121)
Washington State (442)
705,409 Results for "carmot therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy
Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.
July 26, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche’s oral GLP-1 receptor agonist CT-996—obtained in the $2.7 billion acquisition of Carmot Therapeutics—reduced body weight by more than 6% at four weeks versus placebo in a Phase I trial.
July 17, 2024
·
2 min read
·
Tristan Manalac
Deals
Carmot Therapeutics Announces Completion of Acquisition by Roche
Carmot Therapeutics Inc. today announced that its acquisition by the Roche Group (Roche) has been completed.
January 29, 2024
·
3 min read
Drug Development
Roche Sees Early ROI on $2.7B Carmot Buy with Phase I Data for Obesity Candidate
Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.
May 16, 2024
·
2 min read
·
Tristan Manalac
Business
Carmot Therapeutics Appoints Charles W. Newton to Board of Directors
Carmot Therapeutics, Inc. today announced that it has appointed Charles “Charlie” Newton to its Board of Directors.
July 19, 2023
·
2 min read
Deals
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
November 20, 2023
·
2 min read
·
Tristan Manalac
Deals
Roche Jumps into Lucrative Weight-Loss Space with $2.7B Carmot Buy
The acquisition will give Roche access to Carmot’s clinical portfolio of three GLP-1 receptor agonists, placing it squarely in the middle of the competition to treat overweight and obesity.
December 4, 2023
·
2 min read
·
Tristan Manalac
Drug Development
Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes
Carmot Therapeutics Inc. today announced that it has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult participants with overweight or obesity with T1D.
November 15, 2023
·
4 min read
Biotech Bay
Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting
Carmot Therapeutics Inc. today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany.
September 26, 2023
·
3 min read
Drug Development
Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996
Carmot Therapeutics, Inc. today announced preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.
October 10, 2023
·
3 min read
1 of 70,541
Next
